Discontinuation report NORVIR
Report ID | 76354 |
Drug Identification Number | 02229145 |
Brand name | NORVIR |
Common or Proper name | Norvir Oral Solution |
Company Name | ABBVIE CORPORATION |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | RITONAVIR |
Strength(s) | 80MG |
Dosage form(s) | SOLUTION |
Route of administration | ORAL |
Packaging size | 240mL |
ATC code | J05AE |
ATC description | DIRECT ACTING ANTIVIRALS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2019-03-31 |
Actual discontinuation date | 2019-03-31 |
Remaining supply date | 2019-03-31 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | Norvir Oral Solution sales by AbbVie Corporation will cease on March 31, 2019. Last lot available on the market expires in May 2019. |
Company comments | AbbVie routinely and carefully assesses our portfolio, including our existing and anticipated pipeline to determine what is best for our customers and our business. This decision is in line with Norvir’s phase in the product lifecycle. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 8401 TRANS-CANADA HIGHWAY SAINT-LAURENT, QUEBEC CANADA H4S 1Z1 |
Company contact information | Should you require any additional information, please contact our Customer Service Department at 1-888-704-8270. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2019-04-01 | English | Compare |
v4 | 2019-02-20 | French | Compare |
v3 | 2019-02-20 | English | Compare |
v2 | 2019-02-20 | French | Compare |
v1 | 2019-02-20 | English | Compare |
Showing 1 to 5 of 5